<?xml version="1.0" encoding="UTF-8"?>
<p id="Par68">One more vaccine, containing M2 peptides and various conservative CTL epitopes [
 <xref ref-type="bibr" rid="CR114">114</xref>], also passed the first phase of clinical trials (NCT01181336, Imutex Limited). However, this vaccine stimulates cellular immunity and is HLA-specific, which may be a reason for its narrow focus. Also, the cellular immune response is slower than the humoral response, and in the event of a pandemic, it would not effectively prevent infection [
 <xref ref-type="bibr" rid="CR59">59</xref>].
</p>
